Street View: Bristol Myers keeps the ball rolling on growth and pipeline promise
BMY•Analysts point to pipeline data readouts as the key catalyst
J.P. Morgan ("overweight") says the focus remains on BMY's upcoming pipeline data readouts, with milvexian, its investigational blood thinner for stroke prevention, viewed as the key catalyst.
Jefferies ("buy," PT: $73) says BMY's raised revenue outlook appears achievable, supported by strong first-half performance and confidence in the second-half outlook.
Morningstar (fair value: $70) says "Bristol's newer products continue to offset headwinds on older therapies facing generics, but upcoming clinical data readouts will help determine how well this strategy will play out in the long run"
Truist Securities ("buy," PT: $70) says it remains bullish on BMY, citing expected continued momentum in its growth portfolio and key data readouts anticipated in the second half of 2026 and first half of 2027.
Revenue and profit forecast raised after strong second quarter
Drugmaker Bristol Myers Squibb BMY.N lifted its full-year revenue and profit forecast on Thursday as strong sales of blood thinner Eliquis and newer medicines pushed second-quarter results well past analyst estimates.
Median PT of 31 brokerages covering the stock is $63 - LSEG-compiled data.
